Centogene N.V. announced the expansion of MOx, the Company?s multiomic diagnostic portfolio, now incorporating cutting-edge transcriptomic analysis. CENTOGENE?s MOx 2.0 is a single-step multiomic solution that combines DNA sequencing, biochemical testing, and now RNA sequencing to provide physicians with the most comprehensive testing capability. Transcriptomics examines the transcripts to reveal mutation-specific RNA patterns, differences in gene expression, and how cells and tissues respond to environmental or physiological changes.

Using RNA sequencing, a more complete picture of disease biology and response to drugs can be established. MOx 2.0 ? A Paradigm Shift in Real-World Patient Diagnostics: CENTOGENE?s enhanced multiomic portfolio consists of three seamlessly integrated key updates: Highest Diagnostic Yield With Transcriptomics: By integrating RNA sequencing, a more complete picture of disease biology can be established, capturing over an estimated 60% of tested patients with suspected genetic disorders, compared to 40-50% with standard Whole Exome and Genome Sequencing.

Simplified Logistics: Leveraging CentoCard®, CENTOGENE?s filter card technology for extracting high-quality extraction of DNA, RNA, enzymes, and metabolites from dried blood spots, sample collection and shipping has been streamlined ? ensuring accessible multiomic testing for patients worldwide. Unparalleled Insights: Delivering medical reporting based on bioinformatics, artificial intelligence, and medical expert-based analysis of the CENTOGENE Biodatabank with over 800,000 patients represented from over 120 highly diverse countries, as well as more than 70 million unique variants.